WO2023218278 - LONG-TERM GENE THERAPY FOR OVERACTIVE BLADDER
National phase entry is expected:
Publication Number
WO/2023/218278
Publication Date
16.11.2023
International Application No.
PCT/IB2023/054387
International Filing Date
27.04.2023
Title **
[English]
LONG-TERM GENE THERAPY FOR OVERACTIVE BLADDER
[French]
THÉRAPIE GÉNIQUE À LONG TERME POUR VESSIE HYPERACTIVE
Applicants **
UROVANT SCIENCES GMBH
Gotthardstrasse 3
6300 Zug, CH
Inventors
HAAG-MOLKENTELLER, Cornelia
c/o Urovant Sciences, Inc.
5281 California Avenue, Suite 100
Irvine, California 92617, US
MUJAIS, Salim Khalil
c/o Urovant Sciences, Inc.
5281 California Avenue, Suite 100
Irvine, California 92617, US
Priority Data
63/341,357
12.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2109 | |
| EPO | Filing, Examination | 11967 | |
| Japan | Filing | 601 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 5560 |
Total: 20812 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides long-acting gene therapy methods to treat overactive bladder (OAB) and symptoms thereof, or to ameliorate symptoms thereof, comprising the administration of URO-902, a pharmaceutical composition comprising a vector encoding the alpha subunit of the Maxi-K channel. Administration of a single dose of URO-902 via injection into the smooth muscle of the bladder of OAB patients caused clinically relevant reductions from baseline in mean daily micturitions, urgency episodes, and urge urinary incontinence episodes which started at week 2 post-injection, reached a maximum effect at about 12 weeks, and persisted for at 48-week after the injection of the single dose of URO-902.[French]
La présente divulgation concerne des méthodes de thérapie génique à action prolongée pour traiter une vessie hyperactive (OAB) et des symptômes de celle-ci, ou pour améliorer des symptômes de celle-ci, comprenant l'administration d'URO-902, une composition pharmaceutique comprenant un vecteur codant pour la sous-unité alpha du canal Maxi-K. L'administration d'une dose unique d'URO-902 par injection dans le muscle lisse de la vessie de patients souffrant d’une OAB provoquée par des réductions cliniquement pertinentes à partir de la ligne de base dans des mictions quotidiennes moyennes, des épisodes d'urgence, et des épisodes d'incontinence urinaire d'urgence qui commencent à la semaine 2 après l’injection, ont atteint un effet maximal à environ 12 semaines, et persistent pendant 48 semaines après l'injection de la dose unique d'URO-902.